What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study *

Multiple strategies have been used to evaluate the minimal important change (MIC) of the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD). The meaningfulness of these MICs is not well established across all severities of atopic dermatitis (AD).

[1]  S. Feldman,et al.  The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. , 2020, Journal of the American Academy of Dermatology.

[2]  R. Ofenloch,et al.  Interpretability of the Quality Of Life in Hand Eczema Questionnaire (QOLHEQ). , 2020, The Journal of investigative dermatology.

[3]  D. Margolis,et al.  A comparison of five ways to measure atopic dermatitis severity in adults , 2020 .

[4]  D. Margolis,et al.  Validation and interpretation of short form 12 and comparison with dermatology life quality index in atopic dermatitis in adults. , 2019, The Journal of investigative dermatology.

[5]  D. Margolis,et al.  Validation of five patient‐reported outcomes for atopic dermatitis severity in adults , 2019, The British journal of dermatology.

[6]  D. Margolis,et al.  Distribution of atopic dermatitis lesions in United States adults , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  D. Margolis,et al.  Health Utility Scores of Atopic Dermatitis in US Adults. , 2019, The journal of allergy and clinical immunology. In practice.

[8]  D. Margolis,et al.  Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. , 2019, The Journal of investigative dermatology.

[9]  J. Silverberg,et al.  A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. , 2019, Journal of the American Academy of Dermatology.

[10]  J. Silverberg,et al.  Measurement properties of three assessments of burden used in atopic dermatitis in adults , 2018, The British journal of dermatology.

[11]  D. Margolis,et al.  Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  J. Silverberg,et al.  Patient-reported outcomes and quality of life measures in atopic dermatitis. , 2018, Clinics in dermatology.

[13]  J. Silverberg,et al.  Assessing the severity of atopic dermatitis in clinical trials and practice. , 2018, Clinics in dermatology.

[14]  D. Margolis,et al.  Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  J. Silverberg,et al.  Severity strata for five patient‐reported outcomes in adults with atopic dermatitis , 2018, The British journal of dermatology.

[17]  O. Reiter,et al.  Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis , 2018, American Journal of Clinical Dermatology.

[18]  J. Silverberg,et al.  Validation of patient‐reported global severity of atopic dermatitis in adults , 2018, Allergy.

[19]  J. Silverberg,et al.  Relationship between EASI and SCORAD severity assessments for atopic dermatitis. , 2017, The Journal of allergy and clinical immunology.

[20]  J. Silverberg,et al.  Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis , 2017, The British journal of dermatology.

[21]  H. Williams,et al.  Patient‐Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement , 2017, The British journal of dermatology.

[22]  C. Terwee,et al.  Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review , 2017, Allergy.

[23]  A. Armstrong,et al.  Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. , 2016, Journal of the American Academy of Dermatology.

[24]  R. Fitzpatrick,et al.  Floor and ceiling effects in the OHS: an analysis of the NHS PROMs data set , 2015, BMJ Open.

[25]  E. Simpson,et al.  What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study , 2015, The British journal of dermatology.

[26]  L. Puig,et al.  Efficacy of biologics in the treatment of moderate‐to‐severe plaque psoriasis: a systematic review and meta‐analysis of randomized controlled trials with different time points , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  J. Schmitt,et al.  Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME) , 2014, The British journal of dermatology.

[28]  Jochen Schmitt,et al.  Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. , 2013, The Journal of allergy and clinical immunology.

[29]  J. Schmitt,et al.  EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference , 2012, Allergy.

[30]  A. Armstrong,et al.  Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010 , 2011, PloS one.

[31]  C. Terwee,et al.  Linking measurement error to minimal important change of patient-reported outcomes. , 2009, Journal of clinical epidemiology.

[32]  A. Finlay,et al.  The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results , 2008, The British journal of dermatology.

[33]  S. van der Linden,et al.  Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change , 2004, Annals of the rheumatic diseases.

[34]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.

[35]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[36]  A. Trickey,et al.  The European Academy of Dermatology and Venereology Congress , 2015 .

[37]  C. Terwee,et al.  Quality criteria were proposed for measurement properties of health status questionnaires. , 2007, Journal of clinical epidemiology.

[38]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. , 2001, Experimental dermatology.

[39]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .

[40]  A. Taïeb,et al.  Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. , 1993, Dermatology.